TORONTO--(BUSINESS WIRE)--Vital Biosciences today announced that Mr. Douglas Bryant has joined the company’s Board of Directors. Mr. Bryant has more than three decades of industry experience, undertaking multiple global leadership roles at companies like Abbott Laboratories Inc., Luminex Corporation and most recently QuidelOrtho Corporation, where he was President and CEO for 15 years.
Vital Biosciences announced its work on a revolutionary new product, the VitalOne. The VitalOne intends to make lab diagnostics ubiquitous by bringing more than 50 routine lab tests to primary care sites in the form of a simple-to-use device the size of a desktop computer, all from a small sample of blood.
“Doug grew QuidelOrtho into a global leader in diagnostics, and a category defining company in point-of-care,” according to Vasu Nadella, CEO of Vital Biosciences. “His efforts in building pioneering product lines, transformational M&A, responding to COVID-19, and leadership during the acquisition of Ortho Clinical to form QuidelOrtho, all represent a master class in speed, scale and ambition. We are immensely fortunate to have Doug’s expertise on our team.”
Mr. Bryant assumed the role of President and Chief Executive Officer of Quidel Corp. in March 2009. He led the company during the acquisition of Ortho Clinical Diagnostics and subsequent renaming to QuidelOrtho in May 2022. San Diego Business Journal named Mr. Bryant CEO of the Year in 2023.
“Enabling access to testing and care has been one of the guiding tenants in my career. VitalBio’s elegant platform represents an opportunity for me to contribute toward bringing a technological breakthrough in testing closer to patients,” according to Mr. Bryant. “VitalBio is building a future where patients and healthcare providers can spot trends sooner, respond quicker, and chart the course ahead with accuracy and confidence. I’m excited to partner with Vasu and the excellent VitalBio team as they bring the VitalOne through FDA studies and to market.”
Mr. Bryant played a key role in the public health response to the COVID-19 outbreak. Under his leadership, Quidel brought to market the first global rapid antigen test, and rapidly scaled all aspects of research, production, and distribution to get tests in the field by May 8, 2020. In the midst of the pandemic, Bryant also led his team to increase test capacity by tenfold, from approximately 100 million per year to nearly 1 billion tests.
Prior to joining Quidel, Mr. Bryant served as EVP and COO at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics, manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories.
Mr. Bryant will join existing independent Board of Director members Matt Posard, who held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe, and Dr. Marcia Eisenberg, Chief Science Officer and a veteran at LabCorp for more than 25 years.
About Vital Biosciences
Vital Biosciences is a team of scientists and engineers developing advanced diagnostic technologies. Our ecosystem of devices, software, and services aim to make healthcare radically more personalized, proactive, and accessible. For more information, please visit www.vitalbio.com.
